8-K: Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Aprea Therapeutics announced its Q4 and full year 2024 financial results, highlighting progress in clinical trials for APR-1051 and ATRN-119, and a cash balance of $22.8 million.

Summary

• Aprea Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024, along with a business update.
• The company's key programs include APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor.
• The ACESOT-1051 trial evaluating APR-1051 is currently enrolling patients in Cohort 5, with open label safety and efficacy data expected in the second half of 2025.
• The ABOYA-119 trial is evaluating ATRN-119 with a twice daily dosing regimen to maximize clinical benefit, with dose escalation expected to be completed in the second half of 2025.
• Aprea reported cash and cash equivalents of $22.8 million as of December 31, 2024, which is expected to fund operations into the first quarter of 2026.
• The company's operating loss for the fourth quarter of 2024 was $3.2 million, compared to $3.7 million in the fourth quarter of 2023.
• The net loss for the fourth quarter of 2024 was $2.9 million ($0.49 per basic share), compared to a net loss of $3.4 million ($0.92 per basic share) for the same period in 2023.
• For the full year 2024, the company reported an operating loss of $14.3 million, compared to $15.5 million for the year ended December 31, 2023.
• The net loss for the year ended December 31, 2024, was $13.0 million ($2.35 per basic share), compared to a net loss of $14.3 million ($3.95 per basic share) for the comparable period in 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress in its clinical trials and has sufficient cash to fund operations into Q1 2026. However, it is still incurring losses and faces risks associated with clinical development and regulatory approval.

Positives

• Aprea has made excellent progress across its pipeline in 2024.
• APR-1051 appears safe and well tolerated to date with no hematologic toxicity.
• The company believes its cash and cash equivalents will be sufficient to meet its currently projected operating expenses and capital expenditure requirements into the first quarter of 2026.
• The company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations.

Negatives

• The company reported a net loss of $13.0 million for the year ended December 31, 2024.
• The company has an accumulated deficit of $321.0 million as of December 31, 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the success, timing, and cost of ongoing clinical trials.
• The company's ability to continue as a going concern is a risk factor.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.

Future Outlook

Aprea believes its current cash and cash equivalents will be sufficient to meet its projected operating expenses and capital expenditure requirements into the first quarter of 2026.

Management Comments

• We made excellent progress across our pipeline in 2024, laying a strong foundation for the year ahead, said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea.
• We continue to enroll patients in the ACESOT-1051 trial evaluating our WEE1 kinase inhibitor, APR-1051, which we believe has best in class potential.
• Our ultimate goal is to transform the treatment paradigm for difficult to treat cancers by unlocking the full potential of DDR-based therapies.

Industry Context

Aprea is focused on developing DDR-based therapies, which are emerging as a promising approach for treating cancers with specific genetic mutations. The company's programs target WEE1 and ATR, key components of the DNA damage response pathway, aiming to exploit cancer cell vulnerabilities while minimizing damage to healthy cells.

Comparison to Industry Standards

• Aprea's APR-1051 is being developed to address tolerability challenges seen with other WEE1 inhibitors like Adavosertib (AZD-1775) from AstraZeneca and Azenosertib (ZN-c3) from Zentalis Pharmaceuticals.
• The company aims to achieve greater clinical activity with APR-1051 compared to other WEE1 inhibitors currently in development.
• Aprea's ATRN-119 is a macrocyclic ATR inhibitor, potentially offering advantages in selectivity and toxicity compared to first-generation acyclic ATR inhibitors like AZD6738 (AstraZeneca), BAY1895344 (Bayer), and RP-3500 (Repare).

Management Changes

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and financial stability are positive for shareholders.
• Employees: The company's growth and development activities may create opportunities for employees.
• Patients: Successful development of APR-1051 and ATRN-119 could provide new treatment options for patients with cancer.

Next Steps

• Continue enrolling patients in the ACESOT-1051 trial evaluating APR-1051.
• Complete dose escalation in the ABOYA-119 trial evaluating ATRN-119.
• Report open label safety and efficacy data from ACESOT-1051 in the second half of 2025.
• Complete dose escalation in the ABOYA-119 trial in the second half of 2025.
• Complete dose escalation for APR-1051 in H1 2026.

Key Dates

Keywords

APR-1051, ATRN-119, WEE1 inhibitor, ATR inhibitor, Clinical trials, Financial results, Aprea Therapeutics, Oncology, Cancer, Biopharmaceutical